Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Veer Biotechnology's conference call to discuss the company's Veer 5500 strategic collaboration with Astellas in positive phase one data and 2025 financial results. As a reminder, this conference call is being recorded. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. I will now turn the call over to Kiki Patel, head of investor relations. You may begin, Kiki. Thank you, operator, and welcome, everyone. Earlier today, we issued three press releases, including a joint release with Astellas announcing a strategic collaboration with our PSMA-directed T-cell engager, VIR 5500. A second release reporting the Phase 1 VIR 5500 data that will be presented at ASCO GU, and a third release reporting our fourth quarter and year-end earnings. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration outcomes, future results, performance, or achievements to differ significantly from those expressed or implied in such forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the potential benefits of our collaboration with Astellas, that the closing of the Astellas collaboration is subject to the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the therapeutic potential of BEER 5500, our ProX10 platform, our development plans and timelines, financial terms and milestone payments, and our cash runway a...